Treatment of migraine and cluster headache with Psilocybin and MDMA

migraines by about ۱۵%," Schindler said. "Pain was also reduced. There was also a reduction in the functionalimpairment during migraine attack."Schindler and colleagues also performed a similar study evaluatingpsilocybin for the treatment of cluster headaches. "In those who received placebo, compared to baseline, therewas no difference," she said. "But in those who received psilocybin there was about a ۳۰% reduction over ۳weeks.And this was seen out to ۸ weeks." MDMA and psilocybin are two drugs within the psychedelic familybeing investigated in Phase ۱ clinical studies as alternative therapies when treating people living with pain.Scientists have collected data from animal studies establishing that MDMA and psilocybin may work on the ۵-HT۲A receptor among others; however, it is unclear how this and other receptors play a role in chronicpain.These two substances have not been approved for the treatment of pain, but may have potential forcommon psychiatric comorbidities of chronic pain. Use of these drugs requires special considerations related toprovider education and training, appropriate patient selection, role of psychotherapy, and risk mitigationplacebo-controlled study with patients who experienced at least two migraine attacks per week for up to ۶۵weeks."Compared to a placebo, psilocybin reduced the number ofPsychedelic use, specifically psilocybin, is effective in treating cluster headaches and migraines. Schindler andcolleagues used data from various patient reports and surveys to design and conduct early proof-of-conceptstudies using psilocybin to treat migraines and cluster headaches, including a double-blind,